Profile data is unavailable for this security.
About the company
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a don’t eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-166.20m
- Incorporated2020
- Employees74.00
- LocationALX Oncology Holdings Inc323 Allerton AvenueSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 466-7125
- Fax+1 (302) 655-5049
- Websitehttps://alxoncology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma Inc | 68.00k | -228.34m | 698.53m | 224.00 | -- | 1.16 | -- | 10,272.55 | -0.9057 | -0.9057 | 0.0003 | 2.37 | 0.00009 | -- | -- | 303.57 | -29.00 | -- | -30.21 | -- | -- | -- | -335,794.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| SAGE Therapeutics Inc | 91.06m | -503.14m | 704.13m | 487.00 | -- | 0.9976 | -- | 7.73 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Cogent Biosciences Inc | 0.00 | -212.17m | 711.36m | 164.00 | -- | 3.55 | -- | -- | -2.47 | -2.47 | 0.00 | 4.42 | 0.00 | -- | -- | 0.00 | -57.40 | -49.53 | -62.27 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Stoke Therapeutics Inc | 7.85m | -108.53m | 724.47m | 110.00 | -- | 4.61 | -- | 92.35 | -2.42 | -2.42 | 0.1747 | 3.02 | 0.0322 | -- | 31.19 | 71,318.18 | -44.57 | -31.62 | -51.70 | -33.92 | -- | -- | -1,383.40 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| National Research Corporation | 147.42m | 30.36m | 740.20m | 435.00 | 25.01 | 20.04 | 20.38 | 5.02 | 1.24 | 1.24 | 6.02 | 1.55 | 1.16 | -- | 11.53 | 338,896.60 | 23.80 | 26.25 | 35.67 | 36.77 | 62.29 | 63.20 | 20.60 | 23.95 | -- | 132.55 | 0.5325 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
| ALX Oncology Holdings Inc | 0.00 | -166.20m | 740.34m | 74.00 | -- | 4.35 | -- | -- | -3.71 | -3.71 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -67.73 | -34.34 | -76.12 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.067 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Phibro Animal Health Corp | 999.56m | 13.16m | 745.27m | 1.92k | 56.64 | 2.76 | 15.30 | 0.7456 | 0.3249 | 0.3249 | 24.68 | 6.67 | 1.03 | 2.42 | 6.37 | 520,606.30 | 1.35 | 5.46 | 1.66 | 6.83 | 30.33 | 31.41 | 1.32 | 5.11 | 1.67 | 2.26 | 0.6427 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
| Dianthus Therapeutics Inc | 3.22m | -50.21m | 752.21m | 53.00 | -- | 2.02 | -- | 233.31 | -3.20 | -3.20 | 0.2721 | 12.70 | 0.0138 | -- | -- | 60,830.19 | -21.56 | -41.40 | -22.27 | -44.70 | -- | -- | -1,557.51 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| Humacyte Inc | 0.00 | -105.70m | 753.80m | 183.00 | -- | 28.82 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Wave Life Sciences Ltd | 112.91m | -61.67m | 765.71m | 266.00 | -- | 30.16 | -- | 6.78 | -0.5152 | -0.5152 | 0.9985 | 0.2719 | 0.4494 | -- | -- | 424,488.70 | -24.54 | -56.98 | -60.43 | -102.38 | -- | -- | -54.61 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| Praxis Precision Medicines Inc | 2.20m | -125.38m | 776.52m | 82.00 | -- | 2.62 | -- | 353.77 | -15.91 | -15.91 | 0.2394 | 17.32 | 0.0126 | -- | -- | 26,768.29 | -71.89 | -74.04 | -83.56 | -85.12 | -- | -- | -5,711.85 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Hillevax Inc | 0.00 | -143.51m | 787.58m | 90.00 | -- | 3.25 | -- | -- | -3.29 | -3.29 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -46.66 | -- | -50.34 | -- | -- | -- | -- | -- | -- | -- | 0.0963 | -- | -- | -- | 22.68 | -- | -- | -- |
| Regenxbio Inc | 86.73m | -260.15m | 787.60m | 344.00 | -- | 2.01 | -- | 9.08 | -5.88 | -5.88 | 1.96 | 7.97 | 0.126 | -- | 5.00 | 252,110.50 | -37.78 | -16.75 | -45.07 | -19.08 | 56.89 | 78.27 | -299.97 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| Disc Medicine Inc | 0.00 | -80.60m | 795.54m | 74.00 | -- | 2.35 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to ALX Oncology Holdings Inc's reporting currency: US Dollar USD
49.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 7.51m | 14.86% |
| Redmile Group LLCas of 31 Mar 2024 | 4.33m | 8.57% |
| Cormorant Asset Management LPas of 31 Mar 2024 | 3.14m | 6.22% |
| Vestal Point Capital LPas of 31 Mar 2024 | 2.61m | 5.17% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.93m | 3.83% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.52m | 3.01% |
| HBM Partners AG (Investment Management)as of 31 Dec 2023 | 1.50m | 2.97% |
| Citadel Advisors LLCas of 31 Mar 2024 | 1.21m | 2.40% |
| Geode Capital Management LLCas of 31 Mar 2024 | 604.71k | 1.20% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 553.87k | 1.10% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
